Editor's Corner

Publisher's Note: 

From now on, FierceBioResearcher will be published on Tuesdays instead of Thursdays. Based on your feedback, we realized that it would be better to get you this information earlier in the week. Enjoy!  

Best,
Jeff 

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.